Insulin Pump System Now Available for Young Children

Children ages 2 to 17 years will now be allowed to use the Animas Vibe insulin pump and continuous glucose monitoring system for diabetes management.

The FDA recently expanded the product’s indication; the system had already been approved for insulin-requiring diabetic adults.

The system uses Dexcom G4 Platinum CGM technology and is the only product available for patients as young as 2 years.

Children’s caregivers will now be able to monitor glucose data and administer insulin right from the pump.

“CGM-enabled systems, like the Animas Vibe system, provide patients with a more complete glucose picture, which is acutely important for children since they might not always be aware of the symptoms associated with high or low blood sugars,” said Brian Levy, chief medical officer at Animas, in a press release. “The approval of the pediatric indication for Animas Vibe System enables parents and caregivers to both deliver insulin precisely, and monitor glucose trends accurately in children as young as age 2 with 1 integrated device.”

In studies, insulin pump therapy has been shown to significantly improve blood glucose control compared with multiple daily injections.

Some of the features of the Animas Vibe system include waterproof durability, customizable alerts, and a long-wear sensor.